US stock market volatility | FDA plans to require new vaccines to undergo placebo-controlled tests, vaccine sector drops against the market trend

According to the Smart Finance and Economics app, on Thursday, the vaccine sector bucked the market trend and fell. As of the time of writing, GlaxoSmithKline (GSK.US) dropped by more than 1.9%, Sanofi (SNY.US) dropped by nearly 1%, Merck (MRK.US) fell by over 1.2%, AstraZeneca (AZN.US) fell by 1.7%, Pfizer (PFE.US) fell by over 1.5%, BioNTech (BNTX.US) fell by over 2.5%, Moderna (MRNA.US) fell by over 3.7%, and Novavax (NVAX.US) dropped by over 3%. On the news front, according to multiple U.S. media reports citing the Department of Health and Human Services (HHS) on Wednesday night, the U.S. Food and Drug Administration (FDA) is planning to require all new vaccines to undergo placebo-controlled clinical trials before approval. This new policy marks a major shift in the U.S. vaccine approval process.